Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon (Nasdaq: ANNX) granted stock options as inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Annexon (Nasdaq: ANNX) granted stock options as inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

The employees received options to buy 705,000 shares at $4.64 per share, with a ten-year term and four-year vesting schedule.

Positive

• Inducement options for 705,000 shares support recruitment of key non-executive hires
• Four-year vesting with one-year cliff may help employee retention and alignment with shareholders

Negative

• 705,000 stock options at $4.64 per share create potential future dilution for existing shareholders
• Ten-year option term extends the period of potential dilution over a long timeframe

Argus Jun 17 session

+9.29% close to close Open Argus

Details

News Market Reaction – ANNX

On Jun 17, the first trading day after this news, ANNX closed 9.29% above the previous close.

Data tracked by StockTitan Argus for the Jun 17 session.

Market Context

On Jun 17, the first trading day after this news, the stock closed 9.3% above the previous close. A ...

Analysis

On Jun 17, the first trading day after this news, the stock closed 9.3% above the previous close. A strong positive reaction aligns with routine but shareholder-relevant updates when combined with supportive context such as prior Net Buying by insiders and defined clinical milestones from earlier releases. However, today’s announcement centers on option grants for 705,000 shares at $4.64, which are standard employment incentives. Investors would still need to weigh overall valuation, past reactions to similar news, and broader biotech sector volatility when assessing durability.

Key Figures

Patients impacted: 10 million people Inducement options: 705,000 shares Exercise price: $4.64 per share +4 more

Patients impacted

10 million people

Neuroinflammatory diseases targeted by Annexon platform

Inducement options

705,000 shares

Options granted to two new non-executive employees

Exercise price

$4.64 per share

Closing price on June 15, 2026 and grant exercise price

Option term

10 years

Duration of inducement stock options

Vesting period

4 years

Total vesting period for inducement options

Initial vesting

25% at 1 year

Portion of options vesting on first anniversary

Ongoing vesting

1/48th monthly

Monthly vesting schedule after first anniversary

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   Investor conferences

   24h Move

   -2.4%

   Participation in two June 2026 healthcare investor conferences announced.

2. May 18

   Inducement grants

   24h Move

   -1.0%

   Equity inducement options for three new employees under 2022 plan.

3. May 07

   Earnings and pipeline

   24h Move

   +3.1%

   Q1 2026 results plus cash runway and multiple 2026 milestones outlined.

4. May 06

   Conference presentation

   24h Move

   -0.3%

   Planned presentation at Bank of America Securities Health Care Conference.

5. Apr 08

   Conference presentation

   24h Move

   +1.5%

   Participation in the 25th Annual Needham Virtual Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), exercise price, vesting, employment inducement award plan

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"The equity awards were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The options carry a ten-year term and an exercise price per share equal to $4.64..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"...and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

employment inducement award plan financial

"...under the terms of the 2022 Employment Inducement Award Plan."

An employment inducement award plan is a company program that grants stock, stock options, or other equity-based incentives to recruit or retain a specific new employee, similar to offering a signing bonus but paid in company shares. Investors watch these plans because they can dilute existing ownership, change management incentives, and increase compensation expense, all of which can affect share value and future company performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on June 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the two new non-executive employees received options to purchase 705,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $4.64, which was the closing price of Annexon’s common stock on June 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to each employee’s continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did Annexon (ANNX) announce on June 16, 2026?

Annexon announced stock option inducement grants to two new non-executive employees. According to Annexon, the awards cover 705,000 shares of common stock, granted under the 2022 Employment Inducement Award Plan, consistent with Nasdaq Listing Rule 5635(c)(4).

How many Annexon (ANNX) shares are covered by the new employee stock options?

The inducement awards cover options to purchase 705,000 Annexon common shares. According to Annexon, these options were granted to two new non-executive employees as part of hiring packages under the 2022 Employment Inducement Award Plan.

What is the exercise price and term of the new Annexon (ANNX) inducement options?

The options have a ten-year term and an exercise price of $4.64 per share. According to Annexon, $4.64 was the closing price of its common stock on June 15, 2026, the grant date.

How do the Annexon (ANNX) inducement stock options vest for the new employees?

The options vest over four years, subject to continued service. According to Annexon, 25% of the shares vest on the first anniversary of the grant date, with an additional 1/48th vesting monthly thereafter.

Under which plan were the June 2026 Annexon (ANNX) inducement awards granted?

The inducement options were granted under Annexon’s 2022 Employment Inducement Award Plan. According to Annexon, the awards were approved on June 13, 2026, in line with Nasdaq Listing Rule 5635(c)(4).